Transient Receptor Potential Canonical Channel Blockers Improve Ventricular Contractile Functions After

Akiko Kojima, Yutaka Fukushima, Yuki Ito

  • 1Physiology, Shiga University of Medical Science, Otsu, Japan.

Insights

Transient receptor potential canonical (TRPC) channels contribute to heart dysfunction after ischemia. Blocking these channels during reperfusion improved cardiac function, suggesting TRPC channels as a therapeutic target for myocardial ischemia/reperfusion injury.

Area of Science:

  • Cardiovascular Biology
  • Ion Channel Physiology
  • Myocardial Ischemia Research

Background:

  • Ischemia-reperfusion injury causes intracellular calcium overload and cardiac dysfunction.
  • The precise mechanisms of calcium overload, potentially involving store-operated calcium entry, remain unclear.
  • Transient receptor potential canonical (TRPC) channels are implicated in regulating calcium entry.

Purpose of the Study:

  • To investigate the role of TRPC channels in contractile dysfunction following myocardial ischemia-reperfusion.
  • To determine if TRPC channel activity contributes to cardiac dysfunction in a mouse model.

Main Methods:

  • Confirmed functional expression of TRPC channels in mouse ventricular myocytes via immunocytochemistry, Western blotting, and patch-clamp.
  • Utilized a Langendorff-perfused mouse heart model subjected to global ischemia and reperfusion.
  • Assessed left ventricular function (pressure, derivatives) and the effects of TRPC channel blockers (2-aminoethoxydiphenyl borate, La).

Main Results:

  • Left ventricular function significantly deteriorated during reperfusion in control hearts.
  • Administration of TRPC channel blockers during early reperfusion markedly improved left ventricular function.
  • TRPC channel activity is directly linked to the development of contractile dysfunction post-ischemia.

Conclusions:

  • TRPC channels play a critical role in mediating cardiac contractile dysfunction during myocardial reperfusion.
  • TRPC channels represent a promising therapeutic target for mitigating ischemia/reperfusion injury.
  • Targeting TRPC channels could offer a novel strategy for protecting the heart from ischemic damage.

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.8K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
563
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.8K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
981